Italy performed the world's first artificial esophageal transplant

The world's first artificial esophageal transplant has been carried out by Italian doctors this year in the US and they are trying to apply this new technology to treat many other patients.

Two Italian doctors Fabio Triolo and Saverio la Francesca performed esophageal transplants , or food tubes , on a 75-year-old cancer patient in the US three months ago and the patient's health is now quite stable.

Speaking to the Italian daily La Repubblica, the two doctors said: "The new organ in the patient seems to work well and similar transplants will soon be tested with other individuals."

Dr. La Francesca is President of Biostage, a company that develops biotech-based organ transplants to treat cancer and other diseases that threaten human life like related diseases. esophagus, bronchi and trachea.

After transplanting for 3 months, the patient's health is now quite stable.

The partnership between La Francesca and Triolo has been around for more than a decade.

Dr. Triolo established the Center for Renewable Medicine and Cell Therapy at the University of Palermo, Italy in 2007, before moving to Houston, Texas, USA in 2011.

The US Food and Drug Administration (FDA) approved the new technology in May this year and transplantation was implemented shortly afterwards at a Houston clinic.

During the transplantation process, cancer cells in the 75-year-old patient were replaced with an artificial biopsy tube made of synthetic materials and stem cells from the patient's fat tissue. .

Repubblica newspaper said there are 456,000 cases of esophageal cancer in the world each year. For years, parts of the stomach or intestines have been used to replace cancer cells, but this can lead to some complications.

Experts welcomed the new method of transplantation of two doctors La Francesca and Triolo.

The head of the Italian National Implant Center, Alessandro Nanni Costa, judged that: "From a scientific standpoint, this is an important step. However, we still have to be cautious despite the FDA approval. Other clinical trials need to be conducted ".